RU2004117534A - Фармацевтическая композиция, содержащая полипептиды фактора vii и полипептиды фактора v - Google Patents

Фармацевтическая композиция, содержащая полипептиды фактора vii и полипептиды фактора v Download PDF

Info

Publication number
RU2004117534A
RU2004117534A RU2004117534/15A RU2004117534A RU2004117534A RU 2004117534 A RU2004117534 A RU 2004117534A RU 2004117534/15 A RU2004117534/15 A RU 2004117534/15A RU 2004117534 A RU2004117534 A RU 2004117534A RU 2004117534 A RU2004117534 A RU 2004117534A
Authority
RU
Russia
Prior art keywords
factor
factor vii
vii
polypeptide
polypeptide related
Prior art date
Application number
RU2004117534/15A
Other languages
English (en)
Russian (ru)
Inventor
Расмус РЕЙКЕР (DK)
Расмус РЕЙКЕР
Original Assignee
Ново Нордиск Хелт Кэр Аг (Ch)
Ново Нордиск Хелт Кэр Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ново Нордиск Хелт Кэр Аг (Ch), Ново Нордиск Хелт Кэр Аг filed Critical Ново Нордиск Хелт Кэр Аг (Ch)
Publication of RU2004117534A publication Critical patent/RU2004117534A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2004117534/15A 2001-11-09 2002-11-05 Фармацевтическая композиция, содержащая полипептиды фактора vii и полипептиды фактора v RU2004117534A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101660 2001-11-09
DKPA200101660 2001-11-09

Publications (1)

Publication Number Publication Date
RU2004117534A true RU2004117534A (ru) 2005-05-10

Family

ID=8160820

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004117534/15A RU2004117534A (ru) 2001-11-09 2002-11-05 Фармацевтическая композиция, содержащая полипептиды фактора vii и полипептиды фактора v

Country Status (16)

Country Link
EP (1) EP1446149A1 (xx)
JP (1) JP2005511599A (xx)
KR (1) KR20050043734A (xx)
CN (1) CN1596125A (xx)
AU (1) AU2002340779B2 (xx)
BR (1) BR0213953A (xx)
CA (1) CA2464615A1 (xx)
CZ (1) CZ2004543A3 (xx)
HU (1) HUP0401985A3 (xx)
IL (1) IL161544A0 (xx)
MX (1) MXPA04004304A (xx)
NO (1) NO20042380L (xx)
PL (1) PL370634A1 (xx)
RU (1) RU2004117534A (xx)
WO (1) WO2003039584A1 (xx)
ZA (1) ZA200403271B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0302052A3 (en) 1999-07-14 2005-12-28 Novo Nordisk Healthcare Ag Use of fviia or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis
EP2392655A3 (en) 2003-09-09 2012-02-29 Novo Nordisk Health Care AG Coagulation factor VII polypeptides
JP2007520530A (ja) * 2004-02-05 2007-07-26 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 外傷の遅発型合併症の治療のための、ＶＩＩａ因子又はＶＩＩａ因子等価物の使用
FR2894831B1 (fr) * 2005-12-16 2008-02-15 Lab Francais Du Fractionnement Colle biologique exempte de thrombine et son utilisation comme medicament.
EP2004214B1 (en) * 2006-03-16 2012-11-07 STELLARIS PHARMACEUTICALS Aps Local treatment with factor vii
US10407488B2 (en) * 2013-11-04 2019-09-10 The Regents Of The University Of California Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3810080B2 (ja) * 1994-04-22 2006-08-16 ステイヒテイング・セントラール・ラボラトリウム・バン・デ・ブレドトランスフシーデイーンスト・バン・ヘト・ネーデルランドセ・ロデ・クルイス 血液凝固カスケードにおける疾患を検出および治療するための方法および手段
AU7907398A (en) * 1997-06-23 1999-01-04 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function
EP1076698A2 (en) * 1998-05-14 2001-02-21 Battelle Memorial Institute Transgenic plant-derived human blood coagulation factors

Also Published As

Publication number Publication date
EP1446149A1 (en) 2004-08-18
JP2005511599A (ja) 2005-04-28
NO20042380L (no) 2004-06-08
BR0213953A (pt) 2004-08-31
IL161544A0 (en) 2004-09-27
WO2003039584A1 (en) 2003-05-15
PL370634A1 (en) 2005-05-30
AU2002340779B2 (en) 2007-08-02
CZ2004543A3 (cs) 2004-08-18
HUP0401985A3 (en) 2009-03-30
ZA200403271B (en) 2004-11-08
KR20050043734A (ko) 2005-05-11
HUP0401985A2 (hu) 2004-12-28
CN1596125A (zh) 2005-03-16
MXPA04004304A (es) 2004-08-11
CA2464615A1 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
RU2003126911A (ru) Комбинированное применение полипептидов фактора vii и полипептидов фактора ix
ES2193159T5 (es) Una formulación de factor de coagulación viii.
US8580737B2 (en) Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates
US5925738A (en) Methods of production and use of liquid formulations of plasma proteins
KR101212025B1 (ko) 인자 ⅶ 폴리펩티드의 안정화된 고체 조성물
Johnson et al. Clinical investigation of intermediate‐and high‐purity antihaemophilic factor (factor VIII) concentrates
Marder et al. Major surgery in classic hemophilia using fraction I: experience in twelve operations and review of the literature
JPH03170437A (ja) ポリペプチド含有の皮下または筋肉内投与用医薬組成物
RU2004105031A (ru) Фармацевтическая композиция, содержащая полипептиды фактора v11 и полипептиды фактора х1
CA2288737A1 (en) Pharmaceutical preparation comprising vwf propeptide
RU2004117534A (ru) Фармацевтическая композиция, содержащая полипептиды фактора vii и полипептиды фактора v
Aledort Treatment of von Willebrand's disease
RU2006115783A (ru) Терапевтическое применение фактора xi
Scharrer The need for highly purified products to treat hemophilia B
Saulnier et al. Evaluation of desmopressin for dental extractions in patients with hemostatic disorders
Björlin et al. Tooth extractions in hemophiliacs after administration of a single dose of factor VIII or factor IX concentrate supplemented with AMCA
Inada Blood coagulation and autologous blood transfusion in cardiac surgery
RU2004117535A (ru) Фармацевтическая композиция, содержащая полипептиды фактора vii и полипептиды pai-1
Ghirardini et al. Clinical evaluation of subcutaneously administered DDAVP
Escobar Treatment on demand–in vivo dose finding studies
Ghirardini et al. Concentrated DDAVP: further improvement in the management of mild factor VIII deficiencies
Bou Monsef et al. Management of blood products in orthopedic surgery
Ingerslev et al. Efficacy of recombinant factor VIIa (rVIIa) in surgical procedures in haemophilia A patients with inhibitors and congenital factor VII deficiency
Monsef et al. Management of Blood Products in Orthopedic Surgery
US7115559B2 (en) Method for treating coumarin-induced hemorrhage

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20080326